Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.

Prat A, Baselga J.

J Clin Oncol. 2013 May 10;31(14):1703-6. doi: 10.1200/JCO.2012.48.4998. Epub 2013 Apr 8. No abstract available.

PMID:
23569319
[PubMed - indexed for MEDLINE]
2.

[Pharmaceutical therapy of breast cancer].

Láng I, Kahán Z, Pintér T, Dank M, Boér K, Pajkos G, Faluhelyi Z, Pikó B, Eckhardt S, Horváth Z.

Magy Onkol. 2010 Sep;54(3):237-54. doi: 10.1556/MOnkol.54.2010.3.5. Hungarian. No abstract available.

PMID:
20870601
[PubMed - indexed for MEDLINE]
Free Article
3.

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC.

J Natl Cancer Inst. 2008 May 7;100(9):672-9. doi: 10.1093/jnci/djn123. Epub 2008 Apr 29.

PMID:
18445819
[PubMed - indexed for MEDLINE]
Free Article
4.

Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.

Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.

Oncology. 2011;80(5-6):341-9. doi: 10.1159/000330203. Epub 2011 Jul 26.

PMID:
21791944
[PubMed - indexed for MEDLINE]
5.

[HER2-positive breast cancer: standard and double targeted therapy].

Semiglazov VF, Bozhok AA, Semiglazova TIu, Vasil'ev AG, Manikhas AG, Semiglazov VV, Bessonov AA, Nikolaev KS.

Vopr Onkol. 2013;59(3):341-6. Russian.

PMID:
23909035
[PubMed - indexed for MEDLINE]
6.

Treatment of HER2-positive breast cancer: looking backwards briefly.

Puhalla S, Brufsky A.

Lancet Oncol. 2013 Dec;14(13):1250-1. doi: 10.1016/S1470-2045(13)70536-9. Epub 2013 Nov 13. No abstract available.

PMID:
24239207
[PubMed - indexed for MEDLINE]
7.

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.

PMID:
18380893
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.

J Clin Oncol. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.

PMID:
23569311
[PubMed - indexed for MEDLINE]
9.

Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.

Markopoulos C, Xepapadakis G, Venizelos V, Tsiftsoglou A, Misitzis J, Panoussis D, Antonopoulou Z, Stathoulopoulou M, Zobolas V, Gogas H.

Eur J Surg Oncol. 2012 May;38(5):413-9. doi: 10.1016/j.ejso.2012.02.183. Epub 2012 Mar 17.

PMID:
22425282
[PubMed - indexed for MEDLINE]
10.

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.

Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA.

Breast Cancer Res. 2012 May 23;14(3):R83.

PMID:
22621334
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.

Precht LM, Lowe KA, Atwood M, Beatty JD.

Breast J. 2010 Jul-Aug;16(4):362-8. doi: 10.1111/j.1524-4741.2010.00935.x. Epub 2010 Apr 28.

PMID:
20443786
[PubMed - indexed for MEDLINE]
12.

[Current status of treatment for early-stage invasive breast cancer].

Kásler M, Polgár C, Fodor J.

Orv Hetil. 2009 May 31;150(22):1013-21. doi: 10.1556/OH.2009.28615. Hungarian.

PMID:
19465349
[PubMed - indexed for MEDLINE]
13.

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

Prat A, Baselga J.

Nat Clin Pract Oncol. 2008 Sep;5(9):531-42. doi: 10.1038/ncponc1179. Epub 2008 Jul 8. Review.

PMID:
18607391
[PubMed - indexed for MEDLINE]
14.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team.

Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
22257673
[PubMed - indexed for MEDLINE]
15.

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.

Im SA, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW.

Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18.

PMID:
22094934
[PubMed - indexed for MEDLINE]
16.

The predictive value of HER2 in breast cancer.

Piccart M, Lohrisch C, Di Leo A, Larsimont D.

Oncology. 2001;61 Suppl 2:73-82. Review.

PMID:
11694791
[PubMed - indexed for MEDLINE]
17.

[Adjuvant chemotherapy of early stage breast cancer].

Boér K.

Orv Hetil. 2010 Feb 28;151(9):344-53. doi: 10.1556/OH.2010.28824. Review. Hungarian.

PMID:
20159750
[PubMed - indexed for MEDLINE]
18.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

PMID:
19786658
[PubMed - indexed for MEDLINE]
19.

[Modern pharmacological therapy of breast cancer].

Láng I, Kahán Z, Hitre E, Dank M, Rubovszky G, Horváth Z, Kásler M.

Orv Hetil. 2012 Jan 15;153(2):56-65. doi: 10.1556/OH.2012.29257. Review. Hungarian.

PMID:
22217685
[PubMed - indexed for MEDLINE]
Free Article
20.

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

Esteva FJ, Hortobagyi GN.

J Natl Cancer Inst. 2008 Apr 16;100(8):521-3. doi: 10.1093/jnci/djn098. Epub 2008 Apr 8. No abstract available.

PMID:
18398093
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk